Boston Financial Mangement LLC Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO)

Boston Financial Mangement LLC cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,411 shares of the company’s stock after selling 896 shares during the period. Boston Financial Mangement LLC’s holdings in Novo Nordisk A/S were worth $1,412,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. Stanley Laman Group Ltd. purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $282,000. Weaver Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 15.3% in the 3rd quarter. Weaver Capital Management LLC now owns 2,298 shares of the company’s stock worth $274,000 after buying an additional 305 shares in the last quarter. MFA Wealth Advisors LLC boosted its position in shares of Novo Nordisk A/S by 184.4% in the 3rd quarter. MFA Wealth Advisors LLC now owns 728 shares of the company’s stock worth $87,000 after buying an additional 472 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares in the last quarter. Finally, YHB Investment Advisors Inc. boosted its position in shares of Novo Nordisk A/S by 11.3% in the 3rd quarter. YHB Investment Advisors Inc. now owns 3,284 shares of the company’s stock worth $391,000 after buying an additional 334 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 0.5 %

NYSE NVO opened at $83.79 on Friday. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15. The company has a 50-day moving average of $86.39 and a 200-day moving average of $108.48. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $376.02 billion, a P/E ratio of 25.47, a P/E/G ratio of 0.88 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is currently 21.88%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on NVO shares. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.